AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires market-leading companies in niche segments with offerings aimed primarily at the healthcare sector – from research to medical care. The AddLife share has been listed since 2016 on Nasdaq Stockholm, Large Cap. The head office is located in Stockholm.
The Group’s entrepreneur-driven subsidiaries offer high-quality, cost-effective solutions and products to both the private and public sectors. The product portfolio consists partly of self-manufactured products and partly of products made by other manufacturers. The service portfolio includes advisory service, product service and training in all markets where the subsidiaries operate. With this approach AddLife creates added value for customers throughout Europe and builds long-term growth for the Group. AddLife currently has a presence in over 25 countries, mainly in the Nordic region and the rest of Europe.
AddLife acquires and streamlines profitable market-leading niche companies in the field of Life Science. We will attain long-term profitable growth by continuously developing our business and organisation. AddLife combines the strength of a large enterprise with the dedication and business skills of an entrepreneur.
When quick decisions are required, such as during the COVID-19 pandemic, simplicity is important. In collaboration with our suppliers, we developed new purchasing processes and set up delivery plans in an extremely short time so that our customers could perform COVID-19 tests. Simplicity permeates everything we do and streamlines our work.
AddLife owns and develops companies that enhance quality of life, reduce patient suffering and increase social benefit. To achieve this vision, we offer our subsidiaries competitive solutions that meet both the short-term and long-term needs of the customers. Below is our assessment of why AddLife has become a leading, value-generating operator in Life Science.
Sales increased by 52 percent, of which organic growth amounted to 38 percent.
The significant increase in sales in combination with continued good cost control led to a positive earnings effect where EBITA increased by 163 percent compared with 2019. The exceptional result has generated a strong positive operating cash flow, which enables further investments in acquisitions and development for future growth.
